Clomiphene (Clomid) vs Testosterone Cypionate

Mechanism

Clomiphene citrate is a racemic mixture of enclomiphene (trans-isomer, estrogen antagonist) and zuclomiphene (cis-isomer, weak estrogen agonist) that acts as a selective estrogen receptor modulator (SERM). It competitively occupies hypothalamic estrogen receptors, blocking the negative feedback of estradiol on GnRH pulse frequency. This disinhibition increases pulsatile GnRH release, stimulating anterior pituitary gonadotrope secretion of both LH and FSH, which in turn drives testicular testosterone synthesis and spermatogenesis. The zuclomiphene isomer has a much longer half-life (~30 days vs. ~10 days for enclomiphene), leading to tissue accumulation with chronic use.

Standard Dosing

Research indicates 25-50 mg daily or every other day for PCT/HPTA restart protocols. Clinical hypogonadism treatment: 25-50 mg daily.

Timing

Take at the same time daily. Evening dosing may reduce perception of visual side effects. No food timing requirements.

Cycle Duration

PCT protocols: 4-8 weeks. Long-term SERM monotherapy: 3-12 months with periodic reassessment. Zuclomiphene accumulation is a concern beyond 6 months.

Side Effects

• Visual disturbances (blurred vision, floaters, light sensitivity — due to zuclomiphene accumulation)
• Mood swings and emotional lability
• Headache
• Nausea
• Hot flashes
• Gynecomastia (paradoxical, from zuclomiphene's estrogenic activity)
• Elevated estradiol (zuclomiphene accumulation)

Contraindications

• Active liver disease or hepatic dysfunction
• Undiagnosed abnormal uterine bleeding (if prescribed to females)
• Ovarian cysts (females)
• Known hypersensitivity to clomiphene
• Pituitary tumor
• Primary hypogonadism (testicular failure — clomiphene only works in secondary hypogonadism)

Best Stacking Partners

Mechanism

Testosterone cypionate is an esterified prodrug of testosterone that undergoes hydrolysis in vivo to release free testosterone. It binds the androgen receptor (AR), activating genomic pathways via AR nuclear translocation and transcription of anabolic genes including IGF-1, satellite cell proliferation, and nitrogen retention. Additionally, testosterone exerts non-genomic effects through membrane-associated AR signaling, modulating calcium influx and MAPK/ERK pathways. Aromatization to estradiol via CYP19A1 (aromatase) maintains bone density and lipid profiles.

Standard Dosing

Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement therapy.

Timing

Inject on a consistent schedule. Twice-weekly dosing (e.g., Monday/Thursday) reduces peak-trough fluctuations. Morning injection preferred for alignment with circadian testosterone rhythm.

Cycle Duration

Ongoing for TRT. If discontinuing, taper and implement PCT protocol. Testicular function suppression occurs within 2-4 weeks of initiation.

Side Effects

• Polycythemia / elevated hematocrit
• Acne and oily skin
• Testicular atrophy (without hCG)
• Gynecomastia (from aromatization)
• Mood changes and irritability
• Fluid retention
• Elevated liver enzymes (rare with injectable)
• Sleep apnea exacerbation

Contraindications

• Prostate cancer or elevated PSA without urological clearance
• Male breast cancer
• Polycythemia (hematocrit >54%)
• Untreated severe obstructive sleep apnea
• Uncontrolled heart failure
• Desire for near-term fertility (without hCG adjunct)
• Women who are pregnant or may become pregnant

Best Stacking Partners